Celltrion

068270.KO

110.68 USD

-0.38

-0.34%

Overview

Last close

110.68 usd

Market cap

24.10B usd

52 week high

167.56 usd

52 week low

104.55 usd

Target price

165.21 usd

Valuation

P/E

N/A

Forward P/E

33.8983

Price/Sales

9.7216

Price/Book Value

1.9649

Enterprise Value

24.80B usd

EV/Revenue

9.9279

EV/EBITDA

33.008

Key financials

Revenue TTM

2.50B usd

Gross Profit TTM

1.18B usd

EBITDA TTM

639.25M usd

Earnings per Share

N/A usd

Dividend

0.5 usd

Total assets

14.28B usd

Net debt

790.71M usd

About

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets biopharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P44 that is in phase 3 clinical trial for the treatment of multiple myeloma; CT-P51, which is in phase 3 clinical trial for the treatment of Melanoma, lung cancer; CT-P53, which is in phase 3 clinical trial for the treatment of multiple sclerosis; and CT-P55 that is in phase 3 clinical trial for the treatment of Psoriasis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.